GSK Will Pay $3-billion for Avandia, Paxil, Wellbutrin Violations

GlaxoSmithKline agreed to plead guilty and pay a record $3 billion in a deal with federal prosecutors over its marketing of Paxil and Wellburtrin, and for failing to report safety problems with Avandia.

• Drug giant pleads guilty, fined $3B for drug marketing

  WASHINGTON--Prescription drug giant GlaxoSmithKline will plead guilty and pay $3 billion to resolve federal criminal and civil inquiries arising from the… 

• GSK Will Pay $3-billion for Avandia, Paxil, Wellbutrin Violations

    

• GlaxoSmithKline settles healthcare fraud case for $3 billion